Johnson and Johnsons TECVAYLI monotherapy highlights superior survival in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Johnson & Johnson has recently announced their new positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide.

Note that the MajesTEC-9 study evaluated TECVAYLI monotherapy in patients predominantly refractory to anti-CD38 and lenalidomide therapies. These results build on the unprecedented MajesTEC-3 findings published in The New England Journal of Medicine, which showed significant PFS and OS benefits with TECVAYLI plus DARZALEX FASPRO in patients who were naïve or sensitive to an anti-CD38 therapy.

“The MajesTEC-9 results reinforce the potential of TECVAYLI to transform treatment earlier in the multiple myeloma journey, with an immunotherapy regimen widely available for all appropriate patients, including those commonly treated in the community setting,” said Roberto Mina, M.D., Associate Professor, Winship Cancer Institute of Emory University, formerly Assistant Professor, University of Turin, Turin, Italy.* “The impressive results show a significant improvement in progression-free and overall survival as a monotherapy in patients with refractory multiple myeloma, and together with the MajesTEC-3 results, help establish TECVAYLI as an essential therapy for patients as early as first relapse.”

In addition this study evaluates the efficacy and safety of TECVAYLI, a bispecific T-cell engager antibody therapy, versus the standard of care of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

“TECVAYLI continues to break new ground as a first-in-class bispecific T-cell engager antibody and the MajesTEC-9 results are the latest example of Johnson & Johnson’s commitment to provide critical treatment options for patients at every stage of their disease,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Head, Oncology, Johnson & Johnson Innovative Medicine. “In addition to the other transformational therapies in our multiple myeloma portfolio, we continue to redefine the future for patients, bringing us another step closer to cure.”

---

---

Related Topics and Keywords

anti-CD38 therapy, Lenalidomide, multiple myeloma, tecvayli